Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial

David Cameron, Michelle Casey, Cristina Oliva, Beth Newstat, Bradley Imwalle, Charles E. Geyer

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Objectives. A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2+ previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival. Patients and Methods. Women with HER-2+ MBC who progressed after regimens that included, but were not limited to, anthracyclines, taxanes, and trastuzumab, were randomized to lapatinib (1,250 mg/day) plus capecitabine (2,000 mg/m2) or capecitabine monotherapy (2,500 mg/m2) on days 1-14 of a 21-day cycle. Results. At enrollment termination, 399 patients were randomized, and nine were being screened and were offered combination treatment. In total, 207 and 201 patients were enrolled to combination therapy and monotherapy, respectively. Thirty-six patients receiving onotherapy crossed over to combination therapy following enrollment termination. The median overall survival times were 75.0 weeks for the combination arm and 64.7 weeks for the monotherapy arm (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.71-1.08; p=.210). A Cox regression analysis considering crossover as a time-dependent covariate suggested a 20% lower risk for death for patients treated with combination therapy (HR, 0.80;95% CI, 0.64-0.99; p =.043). The low incidence of serious adverse events was consistent with previously reported rates. Conclusions. Although premature enrollment termination and subsequent crossover resulted in insufficient power to detect differences in overall survival, exploratory analyses demonstrate a trend toward a survival advantage with lapatinib plus capecitabine. These data continue to support the efficacy of lapatinib in patients with HER-2+ MBC.

Original languageEnglish (US)
Pages (from-to)924-934
Number of pages11
JournalOncologist
Volume15
Issue number9
DOIs
StatePublished - 2010

Fingerprint

Survival Analysis
Breast Neoplasms
Confidence Intervals
Taxoids
Survival
Anthracyclines
Therapeutics
lapatinib
Capecitabine
Regression Analysis
Incidence

Keywords

  • Breast cancer
  • Capecitabine
  • HER-2
  • Lapatinib
  • Metastatic
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : Final survival analysis of a phase III randomized trial. / Cameron, David; Casey, Michelle; Oliva, Cristina; Newstat, Beth; Imwalle, Bradley; Geyer, Charles E.

In: Oncologist, Vol. 15, No. 9, 2010, p. 924-934.

Research output: Contribution to journalArticle

Cameron, David ; Casey, Michelle ; Oliva, Cristina ; Newstat, Beth ; Imwalle, Bradley ; Geyer, Charles E. / Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : Final survival analysis of a phase III randomized trial. In: Oncologist. 2010 ; Vol. 15, No. 9. pp. 924-934.
@article{63e60ebe6b7c450b955580e56e02a1d5,
title = "Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial",
abstract = "Objectives. A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2+ previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival. Patients and Methods. Women with HER-2+ MBC who progressed after regimens that included, but were not limited to, anthracyclines, taxanes, and trastuzumab, were randomized to lapatinib (1,250 mg/day) plus capecitabine (2,000 mg/m2) or capecitabine monotherapy (2,500 mg/m2) on days 1-14 of a 21-day cycle. Results. At enrollment termination, 399 patients were randomized, and nine were being screened and were offered combination treatment. In total, 207 and 201 patients were enrolled to combination therapy and monotherapy, respectively. Thirty-six patients receiving onotherapy crossed over to combination therapy following enrollment termination. The median overall survival times were 75.0 weeks for the combination arm and 64.7 weeks for the monotherapy arm (hazard ratio [HR], 0.87; 95{\%} confidence interval [CI], 0.71-1.08; p=.210). A Cox regression analysis considering crossover as a time-dependent covariate suggested a 20{\%} lower risk for death for patients treated with combination therapy (HR, 0.80;95{\%} CI, 0.64-0.99; p =.043). The low incidence of serious adverse events was consistent with previously reported rates. Conclusions. Although premature enrollment termination and subsequent crossover resulted in insufficient power to detect differences in overall survival, exploratory analyses demonstrate a trend toward a survival advantage with lapatinib plus capecitabine. These data continue to support the efficacy of lapatinib in patients with HER-2+ MBC.",
keywords = "Breast cancer, Capecitabine, HER-2, Lapatinib, Metastatic, Survival",
author = "David Cameron and Michelle Casey and Cristina Oliva and Beth Newstat and Bradley Imwalle and Geyer, {Charles E.}",
year = "2010",
doi = "10.1634/theoncologist.2009-0181",
language = "English (US)",
volume = "15",
pages = "924--934",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer

T2 - Final survival analysis of a phase III randomized trial

AU - Cameron, David

AU - Casey, Michelle

AU - Oliva, Cristina

AU - Newstat, Beth

AU - Imwalle, Bradley

AU - Geyer, Charles E.

PY - 2010

Y1 - 2010

N2 - Objectives. A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2+ previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival. Patients and Methods. Women with HER-2+ MBC who progressed after regimens that included, but were not limited to, anthracyclines, taxanes, and trastuzumab, were randomized to lapatinib (1,250 mg/day) plus capecitabine (2,000 mg/m2) or capecitabine monotherapy (2,500 mg/m2) on days 1-14 of a 21-day cycle. Results. At enrollment termination, 399 patients were randomized, and nine were being screened and were offered combination treatment. In total, 207 and 201 patients were enrolled to combination therapy and monotherapy, respectively. Thirty-six patients receiving onotherapy crossed over to combination therapy following enrollment termination. The median overall survival times were 75.0 weeks for the combination arm and 64.7 weeks for the monotherapy arm (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.71-1.08; p=.210). A Cox regression analysis considering crossover as a time-dependent covariate suggested a 20% lower risk for death for patients treated with combination therapy (HR, 0.80;95% CI, 0.64-0.99; p =.043). The low incidence of serious adverse events was consistent with previously reported rates. Conclusions. Although premature enrollment termination and subsequent crossover resulted in insufficient power to detect differences in overall survival, exploratory analyses demonstrate a trend toward a survival advantage with lapatinib plus capecitabine. These data continue to support the efficacy of lapatinib in patients with HER-2+ MBC.

AB - Objectives. A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2+ previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival. Patients and Methods. Women with HER-2+ MBC who progressed after regimens that included, but were not limited to, anthracyclines, taxanes, and trastuzumab, were randomized to lapatinib (1,250 mg/day) plus capecitabine (2,000 mg/m2) or capecitabine monotherapy (2,500 mg/m2) on days 1-14 of a 21-day cycle. Results. At enrollment termination, 399 patients were randomized, and nine were being screened and were offered combination treatment. In total, 207 and 201 patients were enrolled to combination therapy and monotherapy, respectively. Thirty-six patients receiving onotherapy crossed over to combination therapy following enrollment termination. The median overall survival times were 75.0 weeks for the combination arm and 64.7 weeks for the monotherapy arm (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.71-1.08; p=.210). A Cox regression analysis considering crossover as a time-dependent covariate suggested a 20% lower risk for death for patients treated with combination therapy (HR, 0.80;95% CI, 0.64-0.99; p =.043). The low incidence of serious adverse events was consistent with previously reported rates. Conclusions. Although premature enrollment termination and subsequent crossover resulted in insufficient power to detect differences in overall survival, exploratory analyses demonstrate a trend toward a survival advantage with lapatinib plus capecitabine. These data continue to support the efficacy of lapatinib in patients with HER-2+ MBC.

KW - Breast cancer

KW - Capecitabine

KW - HER-2

KW - Lapatinib

KW - Metastatic

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77957771125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957771125&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2009-0181

DO - 10.1634/theoncologist.2009-0181

M3 - Article

C2 - 20736298

AN - SCOPUS:77957771125

VL - 15

SP - 924

EP - 934

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -